Last reviewed · How we verify
CHLOROQUINE PHOSPHATE
Chloroquine may work by accumulating in parasite acid vesicles, inhibiting heme polymerization and enzyme activity through DNA interaction.
At a glance
| Generic name | CHLOROQUINE PHOSPHATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1949 |
Mechanism of action
Chloroquine, a 4-aminoquinoline, is believed to fight Plasmodium species by concentrating in the acidic parts of the parasite and preventing the formation of heme polymers. Additionally, it can interfere with certain enzymes by interacting with DNA.
Approved indications
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal cramps
- Headache
- Visual disturbances
- Blurring of vision
- Pruritus
- Anorexia
- Hair loss
Serious adverse events
- Irreversible retinopathy
- Maculopathy
- Macular degeneration
- Cardiomyopathy
- Ventricular fibrillation
- Ventricular tachycardia
- Torsade de pointes
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Aplastic anemia
Key clinical trials
- Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer (PHASE1)
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar (PHASE3)
- The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (NA)
- Hydroxychloroquin (HCQ) in chILD of Genetic Defect (NA)
- Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes (EARLY_PHASE1)
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
- Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHLOROQUINE PHOSPHATE CI brief — competitive landscape report
- CHLOROQUINE PHOSPHATE updates RSS · CI watch RSS